Fortress Biotech Inc.

4.01+0.0400+1.01%Vol 1.19M1Y Perf 84.55%
Apr 20th, 2021 16:00 DELAYED
BID3.97 ASK4.01
Open3.87 Previous Close3.97
Pre-Market- After-Market4.08
 - -  0.07 1.75%
Target Price
10.42 
Analyst Rating
Strong Buy 1.00
Potential %
159.85 
Finscreener Ranking
★★★★+     55.97
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★+     49.15
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★+     43.95
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap380.58M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
50.36 
Earnings Date
10th May 2021

Today's Price Range

3.764.09

52W Range

1.896.10

5 Year PE Ratio Range

-1.60-1.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-7.60%
1 Month
-4.75%
3 Months
16.23%
6 Months
56.03%
1 Year
84.55%
3 Years
-4.52%
5 Years
0.75%
10 Years
-

TickerPriceChg.Chg.%
FBIO4.010.04001.01
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
5.30
5.50
0.45
0.89
-9.60
Leverage Ratio 3.70
ProfitabilityValueIndustryS&P 500US Markets
68.00
-230.80
-218.70
-294.90
-
RevenueValueIndustryS&P 500US Markets
32.68M
0.34
-33.64
74.26
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.18-0.0666.67
Q03 2020-0.28-0.2028.57
Q02 2020-0.28-0.1932.14
Q01 2020-0.29-0.0775.86
Q04 2019-0.29-0.276.90
Q03 2019-0.33-0.44-33.33
Q02 2019-0.46-0.2447.83
Q01 2019-0.58-0.2753.45
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.21-50.00Negative
6/2021 QR-0.21-31.25Negative
12/2021 FY-0.59-7.27Negative
12/2022 FY-0.71-231.48Negative
Next Report Date10th May 2021
Estimated EPS Next Report-0.21
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume1.19M
Shares Outstanding94.91M
Trades Count7.47K
Dollar Volume2.33M
Avg. Volume1.68M
Avg. Weekly Volume2.01M
Avg. Monthly Volume3.67M
Avg. Quarterly Volume1.89M

Fortress Biotech Inc. (NASDAQ: FBIO) stock closed at 4.01 per share at the end of the most recent trading day (a 1.01% change compared to the prior day closing price) with a volume of 1.21M shares and market capitalization of 380.58M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 93 people. Fortress Biotech Inc. CEO is Lindsay A. Rosenwald.

The one-year performance of Fortress Biotech Inc. stock is 84.55%, while year-to-date (YTD) performance is 26.5%. FBIO stock has a five-year performance of 0.75%. Its 52-week range is between 1.89 and 6.1, which gives FBIO stock a 52-week price range ratio of 50.36%

Fortress Biotech Inc. currently has a PE ratio of -6.40, a price-to-book (PB) ratio of 3.90, a price-to-sale (PS) ratio of 11.53, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -16.17%, a ROC of -26.69% and a ROE of -72.20%. The company’s profit margin is -%, its EBITDA margin is -218.70%, and its revenue ttm is $32.68 Million , which makes it $0.34 revenue per share.

Of the last four earnings reports from Fortress Biotech Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Fortress Biotech Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Fortress Biotech Inc. is Strong Buy (1), with a target price of $10.42, which is +159.85% compared to the current price. The earnings rating for Fortress Biotech Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fortress Biotech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fortress Biotech Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.69, ATR14 : 0.48, CCI20 : -24.11, Chaikin Money Flow : 0.06, MACD : 0.16, Money Flow Index : 81.30, ROC : 12.46, RSI : 33.97, STOCH (14,3) : 24.74, STOCH RSI : 0.00, UO : 45.02, Williams %R : -75.27), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fortress Biotech Inc. in the last 12-months were: Robyn M Hunter (Sold 28 450 shares of value $124 611 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

CEO: Lindsay A. Rosenwald

Telephone: +1 781 652-4500

Address: 2 Gansevoort Street, New York 10014, NY, US

Number of employees: 93

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

52%48%

Bearish Bullish

55%45%

News

Stocktwits